title: Predicting prostate cancer many years before diagnosis: how and why?
abstract: Evidence of reduced prostate cancer mortality from randomized trials in Europe supports early detection of prostate cancer with prostate-specific antigen (PSA). Yet PSA screening has generated considerable controversy: it is far from clear that the benefits outweigh risks, in terms of overdiagnosis and overtreatment. One way to shift the ratio of benefits to harm is to focus on men at highest risk, who have more to benefit than average. Neither family history nor any of the currently identified genomic markers offer sufficient risk stratification for practical use. However, there is considerable evidence that the levels of PSA in blood are strongly prognostic of the long-term risk of aggressive prostate cancer. Specifically, it is difficult to justify continuing to screen men aged 60 or older if they have a PSA less than 1 or 2 ng/ml; for men 45-60, intervals between PSA tests can be based on PSA levels, with 2-4-year retesting interval for men with PSA of 1 ng/ml or higher, and tests every 6-8 years for men with PSA <1 ng/ml. Men with the top 10% of PSAs at a young age (PSA ~1.5 ng/ml or higher below 50) are at particularly high risk and should be subject to intensive monitoring.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. vickersa@mskcc.org
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Vickers
authors.forename: Hans
authors.initials: H
authors.lastname: Lilja
mesh_terms: D000368:Aged; D055088:Early Detection of Cancer / Q000379:methods*; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D017430:Prostate-Specific Antigen
references.citation: Int J Cancer. 2008 Sep 1;123(5):1154-9
references.pmid: 18546266
references.citation: Prostate. 2009 Oct 1;69(14):1565-72
references.pmid: 19562736
references.citation: N Engl J Med. 2009 Mar 26;360(13):1320-8
references.pmid: 19297566
references.citation: Eur Urol. 2010 Aug;58(2):275-80
references.pmid: 20171779
references.citation: J Natl Cancer Inst. 1995 Mar 1;87(5):354-60
references.pmid: 7531773
references.citation: N Engl J Med. 2008 Feb 28;358(9):910-9
references.pmid: 18199855
references.citation: Lancet Oncol. 2010 Aug;11(8):725-32
references.pmid: 20598634
references.citation: J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67
references.pmid: 15367568
references.citation: BMJ. 2010 Sep 14;341:c4521
references.pmid: 20843935
references.citation: Urology. 2005 Feb;65(2):343-6
references.pmid: 15708050
references.citation: Cancer. 2011 Mar 15;117(6):1210-9
references.pmid: 20960520
references.citation: Int J Epidemiol. 2007 Apr;36(2):287-9
references.pmid: 17452387
references.citation: Clin Chem. 2006 Feb;52(2):235-9
references.pmid: 16384894
references.citation: Cancer. 2010 Oct 15;116(20):4857-65
references.pmid: 20839233
references.citation: Lancet. 1994 Dec 10;344(8937):1594-8
references.pmid: 7527116
references.citation: JAMA. 1995 Jan 25;273(4):289-94
references.pmid: 7529341
references.citation: JAMA. 1992 Apr 22-29;267(16):2215-20
references.pmid: 1372942
references.citation: Eur Urol. 2011 Apr;59(4):498-505
references.pmid: 21334136